MX366685B - Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. - Google Patents
Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.Info
- Publication number
- MX366685B MX366685B MX2015008555A MX2015008555A MX366685B MX 366685 B MX366685 B MX 366685B MX 2015008555 A MX2015008555 A MX 2015008555A MX 2015008555 A MX2015008555 A MX 2015008555A MX 366685 B MX366685 B MX 366685B
- Authority
- MX
- Mexico
- Prior art keywords
- metformin
- diabetes
- disorders
- combinations
- treatment
- Prior art date
Links
- 229960003105 metformin Drugs 0.000 title abstract 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title abstract 3
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008555A MX2015008555A (es) | 2016-01-22 |
| MX366685B true MX366685B (es) | 2019-07-19 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008555A MX366685B (es) | 2013-01-17 | 2014-01-14 | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (Direct) |
| EP (1) | EP2945618B1 (Direct) |
| JP (1) | JP6445459B2 (Direct) |
| KR (1) | KR102165434B1 (Direct) |
| CN (1) | CN104968341B (Direct) |
| AU (1) | AU2014207748B2 (Direct) |
| CA (1) | CA2896308C (Direct) |
| EA (1) | EA201591123A1 (Direct) |
| ES (1) | ES2687083T3 (Direct) |
| IL (1) | IL239714A0 (Direct) |
| MX (1) | MX366685B (Direct) |
| SG (2) | SG10201704716XA (Direct) |
| WO (1) | WO2014113357A1 (Direct) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060653A1 (en) | 2017-09-22 | 2019-03-28 | Regeneron Pharmaceuticals, Inc. | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
| EP3790549A1 (en) * | 2018-05-08 | 2021-03-17 | vTv Therapeutics LLC | Therapeutic uses of glp1r agonists |
| WO2021196949A1 (zh) * | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
| JP2023528726A (ja) * | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| WO2022146061A1 (ko) * | 2020-12-31 | 2022-07-07 | 동국제약 주식회사 | 신규한 용출률을 나타내는 타다라필 또는 이의 약제학적으로 허용되는 염 및 두타스테리드 또는 이의 약제학적으로 허용되는 염을 포함하는 약제학적 조성물 |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| AU2006311601A1 (en) * | 2005-11-07 | 2007-05-18 | Elixir Pharmaceuticals, Inc. | Combinations of metformin and meglitinide |
| CA2716664C (en) * | 2008-03-07 | 2016-10-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds |
| BRPI1013579A2 (pt) * | 2009-03-30 | 2020-11-03 | Transtech Pharma, Inc. | derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| PL2554183T3 (pl) * | 2009-11-13 | 2018-10-31 | Sanofi-Aventis Deutschland Gmbh | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014207748B2 (en) | 2018-10-11 |
| WO2014113357A1 (en) | 2014-07-24 |
| JP6445459B2 (ja) | 2018-12-26 |
| US20150313908A1 (en) | 2015-11-05 |
| EP2945618A1 (en) | 2015-11-25 |
| EP2945618B1 (en) | 2018-06-13 |
| CA2896308C (en) | 2021-11-09 |
| AU2014207748A1 (en) | 2015-07-09 |
| JP2016505039A (ja) | 2016-02-18 |
| SG10201704716XA (en) | 2017-07-28 |
| HK1210424A1 (en) | 2016-04-22 |
| MX2015008555A (es) | 2016-01-22 |
| CA2896308A1 (en) | 2014-07-24 |
| CN104968341A (zh) | 2015-10-07 |
| KR102165434B1 (ko) | 2020-10-14 |
| ES2687083T3 (es) | 2018-10-23 |
| IL239714A0 (en) | 2015-08-31 |
| SG11201504778UA (en) | 2015-07-30 |
| CN104968341B (zh) | 2020-06-09 |
| EA201591123A1 (ru) | 2015-11-30 |
| KR20150104572A (ko) | 2015-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
| MX2018000362A (es) | Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| MX362190B (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12012502121A1 (en) | Peptide conjugates of glp-1 receptor agonists and gastrin and their use | |
| UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
| PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| MX2020010693A (es) | Uso de peptidos glp-1 de accion prolongada. | |
| MX362527B (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| EA028951B9 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| MX2018010640A (es) | Co-agonistas del glucagon y de glp-1 para el tratamiento de la obesidad. | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| MX347372B (es) | Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa. | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| LT2013018A (lt) | Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus | |
| PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
| PH12017501290A1 (en) | Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: VTV THERAPEUTICS LLC |
|
| HC | Change of company name or juridical status |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC. |
|
| FG | Grant or registration |